文献速递白血病

酪氨酸激酶抑制剂时代儿童慢性髓性白血病慢性期的治疗与随访——塔塔纪念医院儿童慢性髓性白血病队列二十年经验

Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort.
PubMed 文献 · Br J Haematol · 2023-12-14

这项单中心回顾性联合前瞻性研究纳入173例慢性期儿童慢性髓性白血病患者,报告伊马替尼治疗及长期毒性随访经验。中位随访84个月,5年无事件生存率和总生存率分别为96.9%和98.7%,长期毒性以低骨密度(70%)、维生素D不足(80%)和精子质量差(43%)常见,诊断时年龄小于5岁者更易发生生长和内分泌毒性(p=0.009)。

要点

  • 173例患儿中位随访84个月,5年无事件生存率96.9%、总生存率98.7%。
  • 低骨密度70%、维生素D不足80%、精子质量差43%为常见长期毒性。
  • 诊断时年龄小于5岁者更易发生生长和内分泌毒性(p=0.009)。

核心结论

  • 定期监测长期毒性、及时干预以及在可行时尝试停药,可能改善儿童慢性髓性白血病的长期预后。

研究设计与样本

  • 单中心、回顾性联合前瞻性研究,纳入173例接受伊马替尼治疗的慢性期儿童慢性髓性白血病患者,并随访长期毒性。

主要发现

  • 达到完全血液学反应、完全细胞遗传学反应和主要分子学反应的平均(标准差)时间分别为3.05(2.1)个月、10.6(8.4)个月和43.4(31.8)个月,末次随访时59例(34%)未达到深度分子学反应。
  • 10例因反应不佳或反应丢失换用第二代酪氨酸激酶抑制剂(尼洛替尼1例、达沙替尼9例),其中7例存在激酶域突变;3例进展至急变期。
  • 中位随访84(范围3-261)个月时,整个队列5年无事件生存率为96.9%(95%CI:93.4-100),5年总生存率为98.7%(95%CI:96.9-100)。
  • 长期毒性筛查显示低骨密度见于70%、维生素D不足见于80%;其他晚期效应包括身材矮小(27%)、青春期延迟(15%)、精子质量差(43%)及杂类内分泌病(8%)。
  • 诊断时年龄小于5岁的患儿更易发生生长和内分泌毒性(p=0.009)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Tyrosine kinase inhibitors (TKIs) have drastically improved the outcomes of pCML (paediatric CML) but data on long-term off-target toxicities of TKIs in children are scarce. In this single-centre, retrospective cum prospective study of pCML in chronic phase, we report our experience of treating 173 children with imatinib and following them for long-term toxicities. Mean (SD) time to attain CHR, CCyR and MMR were 3.05 (2.1), 10.6 (8.4) and 43.4 (31.8) months respectively. DMR was not attained in 59 (34%) patients at last follow-up. Ten patients were switched to second-generation TKIs (2G-TKIs; nilotinib = 1/dasatinib = 9) due to poor/loss in response, of which seven had kinase domain mutations. Three patients progressed to the blastic phase. At a median follow-up of 84 (3-261) months, the 5-year EFS and OS for the entire cohort were 96.9% (95% CI: 93.4-100) and 98.7% (95% CI: 96.9-100) respectively. Screening for long-term toxicities revealed low bone density and hypovitaminosis D in 70% and 80% respectively. Other late effects included short stature (27%), delayed puberty (15%), poor sperm quality (43%) and miscellaneous endocrinopathies (8%). Children younger than 5 years at diagnosis were more susceptible to growth and endocrine toxicities (p = 0.009). Regular monitoring for long-term toxicities, timely intervention and trial of discontinuation whenever feasible are likely to improve the long-term outlook of pCML.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Roy Moulik N, Keerthivasagam S, Pandey A, et al. Treatment and follow-up of children with chronic myeloid leukaemia in chronic phase (CML-CP) in the tyrosine kinase inhibitor (TKI) era-Two decades of experience from the Tata Memorial Hospital paediatric CML (pCML) cohort. Br J Haematol. 2023. PMID: 38098201. doi:10.1111/bjh.19251

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。